Psychopharmacologic approaches to borderline syndromes.
D000786:Anger / Q000187:drug effects; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001007:Anxiety / Q000150:complications; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D001883:Borderline Personality Disorder / Q000150:complications / Q000188:drug therapy*; D003072:Cognition Disorders / Q000150:complications; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D019964:Mood Disorders / Q000150:complications; D019965:Neurocognitive Disorders / Q000188:drug therapy; D010554:Personality Disorders / Q000150:complications / Q000188:drug therapy*; D012559:Schizophrenia / Q000150:complications; D012569:Schizotypal Personality Disorder / Q000175:diagnosis
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D008996:Monoamine Oxidase Inhibitors